Abatacept

Selective T Cell Costimulation Modulator — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Abatacept is a drug in the Selective T Cell Costimulation Modulator class catalogued in DrugCentral. It was first approved by the FDA in 2005. DrugCentral lists 2 molecular targets, including CD80 and CD86. Recorded indications include Juvenile idiopathic arthritis and Rheumatoid arthritis.

• Drug class: Selective T Cell Costimulation Modulator.
• Molecular targets: CD80 and CD86 (2 listed in DrugCentral).
• Indications: Juvenile idiopathic arthritis and Rheumatoid arthritis.
• ATC code: L04AA24 (Selective immunosuppressants).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Juvenile idiopathic arthritis
• Rheumatoid arthritis

Mechanism & targets

• Established pharmacologic class: Selective T Cell Costimulation Modulator

Molecular targets (2)

Target	Gene	Action	Activity
T-lymphocyte activation antigen CD80	CD80	inhibitor	Kd 7.92
T-lymphocyte activation antigen CD86	CD86	inhibitor	Kd 7.92

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2020-02-21	PMDA	—	Bristol-Myers Squibb K.K.
2005-12-23	FDA	—	BRISTOL MYERS SQUIBB

ATC classification

ATC code	Therapeutic hierarchy
L04AA24	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Joint swelling	13332.3
Contraindicated product administered	10160.3
Drug ineffective	7635.9
Arthralgia	6160.5
Synovitis	5970.6
Drug intolerance	5575.6
Arthropathy	5410.2
Treatment failure	4822.7
Pemphigus	4495.7
Systemic lupus erythematosus	4296.4
Pain	4281.5
Therapeutic product effect decreased	4098.3

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Abatacept used for?

DrugCentral lists the following indications for Abatacept: Juvenile idiopathic arthritis and Rheumatoid arthritis.

How does Abatacept work?

Its molecular targets in DrugCentral include CD80 (inhibitor) and CD86 (inhibitor).

When was Abatacept first approved?

Abatacept was first approved by the FDA in 2005.

What drug class does Abatacept belong to?

Abatacept is in the Selective T Cell Costimulation Modulator class.

Sources

• DrugCentral drug card 5089 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201823 — compound record and bioactivity
• DrugBank DB01281 — drug record
• FDA UNII 7D0YB67S97 — substance identity
• DailyMed: FDA labels for Abatacept — current prescribing information (label search)
• UniProt P33681 (CD80) — target protein
• UniProt P42081 (CD86) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.